First Batch Of DRDO And Dr Reddy's 2-DG COVID-19 Drug To Be Launched Early Next Week

·1-min read

In a boost for the national efforts against the COVID-19 pandemic, the first batch of 2-deoxy-D-glucose (2-DG) drug will be launched next week, reports Livemint.

The drug has been developed by the DRDO lab, Institute of Nuclear Medicine and Allied Sciences, in collaboration with Hyderabad based pharmaceutical major Dr Reddy’s Laboratories to treat moderate to severe Covid-19 cases.

The 2-DG has been cleared by the Drug Controller General of India (DCGI) for emergency use in the treatment of Covid-19 patients earlier last week.

The first batch will comprise of 10,000 doses of 2-DG. It will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.

A DRDO statement had earlier said that the clinical trial showed that the drug helps in faster recovery of hospitalized patients and reduces supplemental oxygen dependence. The patients treated with 2-DG showed faster symptomatic cure than Standard of Care (SoC) on various endpoints in the efficacy trends.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting